Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 662 clinical trials
IORT in Local Advanced Laryngocarcinoma (ILAL)

radiotherapy (IORT) in head and neck cancer has been demonstrated in multiple institutional (3-5) studies to optimize local control. It is still unclear whether IORT can improve the local control and have

  • 0 views
  • 27 Feb, 2022
  • 1 location
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

2 randomized controlled trial is to determine the optimal dosage and effectiveness of intratympanic NAC injection in reducing hearing loss in head & neck cancer patients receiving cisplatin

  • 3 views
  • 28 Feb, 2022
  • 1 location
A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study

head and neck cancer. This study investigates the effectiveness of pablizumab in combination with cisplatin and 5-FU for the adjuvant treatment of recurrent, unresectable temporal bone cancer. temporal

  • 0 views
  • 04 Oct, 2022
  • 1 location
NPC - AXEL Study : Axitinib-Avelumab

Nasopharyngeal cancer (NPC) is the most common head and neck cancer in South China and South East Asia. Worldwide, there are 80,000 incident cases and 50,000 deaths annually. In Hong Kong, NPC

  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 3 views
  • 27 Oct, 2022
  • 4 locations
First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors

, head and neck cancer, and melanoma. The total duration of the study will be approximately 4 years and 7 months. Each participant in the study will visit the study site twice before starting

  • 0 views
  • 28 Oct, 2022
  • 1 location
Inhibition of Oral Tumorigenesis by Antitumor B

This is a randomized, double-blinded, placebo-control window of opportunity study of Anti-tumor B versus placebo. Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.

  • 0 views
  • 16 May, 2022
  • 1 location
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in n=6 patients with solid tumors

  • 0 views
  • 25 May, 2022
  • 1 location
Hypopharynx ICG to Reduce the Fistula Rate in Patients Undergoing Salvage Laryngectomy

A laryngectomy involves removing the voice box from the throat. After the voice box has been removed from the throat, the surgeon sews the throat closed. Sometimes part of the throat does not heal and saliva runs out of the throat. This is called a fistula. When a fistula happens, …

  • 0 views
  • 14 Jun, 2022
  • 1 location
Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

The purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would apply to help select patients for this treatment in the future.

  • 3 views
  • 07 Oct, 2022
  • 1 location